Tech Center 1600 • Art Units: 1648 1671
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18166743 | MANNOSE CONJUGATED CHITOSAN-BASED INFLUENZA NANOVACCINE FORMULATIONS AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18312927 | LIVE-ATTENUATED FLAVIVIRUSES WITH HETEROLOGOUS ANTIGENS | Non-Final OA | Katholieke Universiteit Leuven |
| 17760180 | POLYPEPTIDES AND THEIR USE | Non-Final OA | University of Washington |
| 18403028 | SITE-SPECIFIC ANTIBODY-DRUG GLYCONJUGATES AND METHODS | Final Rejection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. |
| 18747563 | Antibodies to Andes Hantavirus, and Methods for Using Same | Final Rejection | Universidad De Concepcion |
| 18656948 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS | Final Rejection | INOVIO PHARMACEUTICALS, INC. |
| 18393160 | HUMAN HERPESVIRUS IMMUNOTHERAPY | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 17763687 | IMMUNOASSAY FOR HEPATITIS B VIRUS CORE-RELATED ANTIGEN AND KIT THEREFOR | Final Rejection | FUJIREBIO INC. |
| 18067358 | EFFICIENT VACCINE | Non-Final OA | VLP Therapeutics Japan, INC. |
| 18149742 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | Non-Final OA | Takeda Vaccines, Inc. |
| 16974123 | Localized activation of virus replicatio boosts herpesvirus-vectored vaccines | Non-Final OA | HSF Pharmaceuticals SA |
| 17786124 | TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS | Final Rejection | UNIVERSITÉ PAUL SABATIER TOULOUSE III |
| 17666338 | SYSTEMS AND METHODS FOR DETECTING THE PRESENCE OF AN ANALYTE, SUCH AS SARS-COV-2, IN A SAMPLE | Final Rejection | ADL Diagnostics, Inc. |
| 17260041 | METHODS FOR GENERATING BROADLY REACTIVE, PAN-EPITOPIC IMMUNOGENS, COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | University of Georgia Research Foundation |
| 17058565 | VIRUS-LIKE PARTICLE COMPOSITIONS AND METHODS OF USING SAME | Non-Final OA | Britt Koskella |
| 16860765 | In-Vitro Method and Device for Detecting a Target Nucleic Acid | Final Rejection | ICHORtec GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy